Abstract Lung cancer is the most common cause of cancer-related death in the world, however lung cancer screening has not been implemented in France at a population level. A recent stydy in France showed that in real life without screening, 21% of lung cancer were diagnosed at early stage while the main prognostic factor in lung cancer is the stage at diagnosis. Low-dose computed tomography (LDCT) screening for lung cancer substantially reduces mortality from lung cancer, as revealed in randomized controlled trials. This study assessed the feasibility and efficacy of lung cancer screening within a real-life context in a French hospital through the installation of screening kiosks. The primary objective of our study was to assess the diagnostic performance of LDCT for lung cancer sreening by using the lung RADS classification updated in 2022. Lung-RADS represents a categorical system published by the American College of Radiology to standardise management in lung cancer screening. Among The secondary objectives, we analyzed the stages of diagnosis and the impact of screening on smoking cessation. Methods Depitab was a single arm prospective study. Participants were recruited between december 2022 and april 2024. Inclusion criteria were, asymptomatic subjects aged between 50 and 80 years old, smokers or former smokers of ≥ 15 pack-years with. The main exclusion criteria were a history of cancer within the last 5 years and comorbidities contraindicating thoracic surgery. The two first years, an annual LDCT was performed and at the date cut-off, two screening rounds were performed. Subjects were recorded by screening kiosks, then pulmonologists checked the criteria and prescribed the LDCT. Findings : between december 2022 and april 2024, 925 subjects were enrolled and 923 underwentLDCT. 875 completed the two round. 12 lung cancers were diagnosed and 9 cancers (75%) were stage 1 or 2 and 10 cancers were treated (83%) were treated surgically. In this study, the overall positive predictive value for a positive screening was 48% because 27 subjects were screened positive but were not subsequenty diagnosed with cancer. Among smoking patients at inclusion, 75/384 (19%) stopped smoking. Conclusion This study demonstrated the feasibility and efficacy of lung cancer screening in a real-life context with most lung cancers diagnosed at an early stage and surgically removed. The rate of false positive was lower compared to NLST study, and similar to nelson study by using an other classification with difference in the nodule management. This abstract is funded by: None
Boyer et al. (Fri,) studied this question.